$6.80—Stale · unknown old
XETRA • Last print unknown ago
$6.80—Stale · unknown old
Biofrontera AG specializes in dermatological products, particularly its flagship product Ameluz, used for the treatment of actinic keratosis. The company operates primarily in Europe and the U.S., leveraging a strong gross margin of 78.7% to maintain competitive pricing in a niche market.
Biofrontera generates revenue through the sale of its proprietary dermatological treatments, particularly Ameluz, which has a unique formulation that allows for effective treatment of skin conditions. The company's competitive advantage lies in its patented product formulations and established distribution networks in key European markets.
Regulatory approvals for new products
Sales growth of Ameluz in the U.S. market
Partnerships or collaborations with larger pharmaceutical companies
Market expansion into Asia-Pacific regions
Regulatory changes impacting drug approvals and pricing
Technological disruption in dermatological treatments
Emergence of generic alternatives to Ameluz
Increased competition from larger pharmaceutical companies
High debt-to-equity ratio (1.27) indicating potential liquidity issues
Negative net margins could impact future financing options
moderate - The demand for dermatological treatments can be affected by consumer spending, but healthcare spending tends to be more resilient during economic downturns.
Low - The company is not heavily reliant on debt for financing, thus rising interest rates have minimal impact on its operations.
minimal - Biofrontera's operations are not significantly affected by credit conditions due to its low debt levels.
growth - Investors are likely attracted to the potential for rapid revenue growth in niche dermatological markets.
high - The stock has shown significant volatility, evidenced by a 3-month return of 2026.3%.